Search


	Podcast:		BioCentury This Week
	Episode:		Ep. 235 - Psychedelic Setback, FDA's Platform Play & ASCO Innovations
	Category:		Science & Medicine
	Duration:		00:29:30
	Publish Date:		2024-06-10 23:00:00
	Description:		A snub by an FDA advisory committee for an MDMA-psychotherapy combination is unlikely to read through to other psychedelic therapies in the pipeline. On the BioCentury This Week podcast, BioCentury’s editors discuss the shortcomings of the Lykos Therapeutics product’s clinical development program and why other psychedelics likely won’t face the same hurdles. The editors also assess FDA’s new platform technology designation and the first-in-human clinical trials described at this year’s American Society of Clinical Oncology (ASCO) meeting. This week’s podcast is sponsored by Nxera Pharma. 00:01 - Sponsor Message: Nxera Pharma 01:41 - Psychedelic Setback 12:38 - FDA's Platform Play 21:39 - ASCO Innovations
	Total Play:		0